Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting
- 1 October 2000
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 22 (10) , 1204-1212
- https://doi.org/10.1016/s0149-2918(00)83063-5
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertensionAmerican Journal of Ophthalmology, 2000
- Adjunctive Therapy With Brinzolamide 1% Ophthalmic Suspension (Azopt®) in Patients With Open-Angle Glaucoma or Ocular Hypertension Maintained on Timolol TherapySurvey of Ophthalmology, 2000
- Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertensionAmerican Journal of Ophthalmology, 1998
- DorzolamideDrugs & Aging, 1997
- A Double-Masked, Randomized 1-Year Study Comparing Dorzolamide (Trusopt), Timolol, and BetaxololArchives of Ophthalmology (1950), 1995
- Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase InhibitorArchives of Ophthalmology (1950), 1992
- Effect of Changing Medication Regimens in Glaucoma PatientsOphthalmologica, 1988
- Treatment AdherenceThe British Journal of Psychiatry, 1976
- Shall We Count Numbers of Eyes or Numbers of Subjects?Archives of Ophthalmology (1950), 1973
- Long-Term Acetazoleamide (Diamox) Administration in Therapy of GlaucomasArchives of Ophthalmology (1950), 1955